Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17147489 | 0.84 | CA1 (0.43) | CA1CA2 | |
| SCHEMBL13849291 | 0.78 | CA12 (0.37) | — | |
| SCHEMBL13849323 | 0.74 | ALOX5AP (0.31) | — | |
| SCHEMBL3718883 | 0.72 | — | — | |
| SCHEMBL17149388 | 0.70 | GRIA4 (0.37) | CA1CA2 | |
| SCHEMBL2004946 | 0.69 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL28095363 | 0.69 | PMP22 (0.40) | — | |
| SCHEMBL1769061 | 0.69 | PMP22 (0.40) | — | |
| SCHEMBL17147396 | 0.68 | CA12 (0.44) | CA1CA2 | |
| SCHEMBL22002855 | 0.68 | GRIA1 (0.50) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-02-06 | — | — | US | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-9884841-B2 | Small molecule inhibitors of Mcl-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-06 | — | — | US | disclosed |
| US-9394303-B2 | Small molecule inhibitors of MCL-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | DYRK1A, DYRK2, DYRK1B | CA1 2172/4885CA2 1567/4885 |
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, API5 | CA1 4838/4885CA2 4717/4885 |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | CA1 4121/4885CA2 3192/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | CA1 4121/4885CA2 3192/4885 |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | CA1 1816/4885CA2 726/4885 |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | CA1 4121/4885CA2 3192/4885 |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | CA1 4121/4885CA2 3192/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | CA1 4121/4885CA2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.